UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/19.03.25 Stock UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/19.03.25
Add to a list
To use this feature you must be a member
Log inSign up

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/19.03.25 Share Price

Warrant

DE000HD441Y5

Market Closed - Börse Stuttgart 19:39:14 24/05/2024 BST
2 EUR +12.36% Intraday chart for UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/19.03.25
Current month+153.16%
1 month+100.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart VERTEX PHARMACEUTICALS INCORPORATED
Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/19.03.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
Vertex to Participate in Upcoming June Investor Conferences BU
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment MT
More news

Quotes 5-day view

Date Price Change
24/05/24 2 +12.36%
23/05/24 1.78 +5.33%
22/05/24 1.69 +2.42%
21/05/24 1.65 -9.34%
20/05/24 1.82 +8.33%

Delayed Quote Börse Stuttgart

Last update May 24, 2024 at 07:39 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying VERTEX PHARMACEUTICALS INCORPORATED
IssuerLogo Issuer UniCredit UniCredit
WKN HD441Y
ISINDE000HD441Y5
Date issued 25/03/2024
Strike 550 $
Maturity 19/03/2025 (298 Days)
Parity 10 : 1
Emission price 1.99 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.03 €
Lowest since issue 0.72 €
Delta0.33x
Omega 6.889
Premium25.19x
Gearing20.7x
Moneyness 0.8308
Difference Strike 93.05 $
Difference Strike %+16.92%
Spread 0.05 €
Spread %2.43%
Theoretical value 2.035
Implied Volatility 27.67 %
Total Loss Probability 75.26 %
Intrinsic value 0.000000
Present value 2.035
Break even 572.07 €
Theta-0.06x
Vega0.14x
Rho0.1x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457 USD
Average target price
462.8 USD
Spread / Average Target
+1.28%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant